Dr. Meredith E. Clement, MD
Infectious Disease (Infectious Disease Physician)
12605 E 16th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 21
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Perelman School of Med at the University of Pennsylvania
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
CO license CDR.0007236 · LA license 310608 -
Internal Medicine Physician
CO license CDR.7236 · LA license 310608
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University Medical Center New Orleans New Orleans, LA
Medical groups
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 21
- Services billed
- 36
- Patients’ average age
- 60
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 27 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Aurora, CO | 176 |
| Biktarvy (bictegrav/emtricit/tenofov ala) | 136 |
| Amlodipine Besylate Other prescribers in Aurora, CO | 87 |
| Metformin Hcl Other prescribers in Aurora, CO | 75 |
| Tivicay (dolutegravir sodium) | 73 |
| Tamsulosin Hcl Other prescribers in Aurora, CO | 72 |
| Lisinopril Other prescribers in Aurora, CO | 63 |
| Losartan Potassium Other prescribers in Aurora, CO | 51 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Aurora, CO | 49 |
| Fluticasone Propionate Other prescribers in Aurora, CO | 47 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 27 payments worth $28,494 in total to this clinician.
| Gilead Sciences, Inc. | $15,720 |
|---|---|
| Viiv Healthcare Company | $9,276 |
| Merck Sharp & Dohme LLC | $3,498 |
| Consulting Fee | $23,652 |
|---|---|
| Travel and Lodging | $4,192 |
| Food and Beverage | $649 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Nov 24, 2025 | Consulting FeeCompany’s description;4288048;SAP;11516719 | $7,610 |
| Viiv Healthcare Company May 22, 2025 | Consulting Fee | $5,553 |
| Gilead Sciences, Inc. Apr 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $5,000 |
| Gilead Sciences, Inc. Jun 18, 2025 | Consulting FeeCompany’s description;4033409;SAP;11516719 | $2,889 |
| Viiv Healthcare Company Apr 7, 2025 | Consulting Fee | $2,600 |
| Merck Sharp & Dohme LLC Jun 25, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Mexico City, Mexico · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $1,902 |
| Viiv Healthcare Company Apr 8, 2025 | Travel and Lodging travel to Durham, NC · in-kind | $688 |
| Merck Sharp & Dohme LLC Aug 11, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Mexico City, Mexico Company’s descriptionProvided as part of a clinical research engagement. | $588 |
| Merck Sharp & Dohme LLC Jun 25, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Mexico City, Mexico · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $274 |
| Merck Sharp & Dohme LLC Jun 26, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Mexico City, Mexico · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $274 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Nov 24, 2025 | Consulting FeeCompany’s description;4288048;SAP;11516719 | $7,610 |
| Gilead Sciences, Inc. Nov 24, 2025 | Travel and Lodging travel to Madrid, Spain Company’s description;4288047;SAP;11516719 | $116 |
| Merck Sharp & Dohme LLC Aug 11, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Mexico City, Mexico Company’s descriptionProvided as part of a clinical research engagement. | $588 |
| Merck Sharp & Dohme LLC Aug 11, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Mexico City, Mexico Company’s descriptionProvided as part of a clinical research engagement. | $105 |
| Merck Sharp & Dohme LLC Jun 26, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Mexico City, Mexico · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $274 |
| Merck Sharp & Dohme LLC Jun 25, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Mexico City, Mexico · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $1,902 |
| Merck Sharp & Dohme LLC Jun 25, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Mexico City, Mexico · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $274 |
| Merck Sharp & Dohme LLC Jun 25, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Mexico City, Mexico · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $88.03 |
| Gilead Sciences, Inc. Jun 18, 2025 | Consulting FeeCompany’s description;4033409;SAP;11516719 | $2,889 |
| Viiv Healthcare Company May 22, 2025 | Consulting Fee | $5,553 |
| Viiv Healthcare Company May 22, 2025 | Travel and Lodging travel to Durham, NC | $127 |
| Viiv Healthcare Company Apr 8, 2025 | Travel and Lodging travel to Durham, NC · in-kind | $688 |
| Viiv Healthcare Company Apr 8, 2025 | Travel and Lodging travel to Durham, NC · in-kind | $31.41 |
| Viiv Healthcare Company Apr 7, 2025 | Consulting Fee | $2,600 |
| Gilead Sciences, Inc. Apr 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $5,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $233,626 in research payments for these studies, mostly to the institutions running them.
- A phase 2B single arm, repeat dose study to evaluate the pharmacokinet
Viiv Healthcare Company - A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Tra…
Gilead Sciences, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.